Paper39376992
Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response.
González MDR and 5 others. Front Oncol, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response. Papers, record 39376992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39376992
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA249054 | NCI NIH HHS | United States | R01CA249054 | PubMed |
Source NIH RePORTER
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19230772 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19230772 | PubMed |
| 2 | 24382349 | Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. | J Clin Invest | 2014 | https://conductscience.org/library/papers/24382349 | PubMed |
| 3 | 28723562 | Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. | Cell Rep | 2017 | https://conductscience.org/library/papers/28723562 | PubMed |
| 4 | 34448832 | 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. | Blood Adv | 2021 | https://conductscience.org/library/papers/34448832 | PubMed |
| 5 | 27959731 | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959731 | PubMed |
| 6 | 16778146 | Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. | Blood | 2006 | https://conductscience.org/library/papers/16778146 | PubMed |
| 7 | 15793220 | FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. | Oncologist | 2005 | https://conductscience.org/library/papers/15793220 | PubMed |
| 8 | 20026804 | Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20026804 | PubMed |
| 9 | 27526324 | Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. | Nat Genet | 2016 | https://conductscience.org/library/papers/27526324 | PubMed |
| 10 | 20220779 | Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. | Leukemia | 2010 | https://conductscience.org/library/papers/20220779 | PubMed |
| 11 | 32296439 | 5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma. | Front Immunol | 2020 | https://conductscience.org/library/papers/32296439 | PubMed |
| 12 | 16076868 | Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. | Blood | 2005 | https://conductscience.org/library/papers/16076868 | PubMed |
| 13 | 37422676 | Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review. | Exp Hematol Oncol | 2023 | https://conductscience.org/library/papers/37422676 | PubMed |
| 14 | 18467609 | Myelodysplastic syndromes. | Blood | 2008 | https://conductscience.org/library/papers/18467609 | PubMed |
| 15 | 27926740 | A 17-gene stemness score for rapid determination of risk in acute leukaemia. | Nature | 2016 | https://conductscience.org/library/papers/27926740 | PubMed |
| 16 | 25943181 | Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. | Leukemia | 2015 | https://conductscience.org/library/papers/25943181 | PubMed |
| 17 | 12011120 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | J Clin Oncol | 2002 | https://conductscience.org/library/papers/12011120 | PubMed |
| 18 | 23242597 | The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. | Haematologica | 2013 | https://conductscience.org/library/papers/23242597 | PubMed |
| 19 | 29214694 | Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. | Am J Hematol | 2018 | https://conductscience.org/library/papers/29214694 | PubMed |
| 20 | 22124213 | DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. | Leukemia | 2012 | https://conductscience.org/library/papers/22124213 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42340493 | Predicting response to hypomethylating agents in myeloid neoplasms: a robust model. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42340493 | PubMed |
| 42184718 | The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42184718 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD34 | 947 | PubTator's text mining | https://conductscience.org/library/genes/947 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39376992
GET https://conductscience.org/api/papers/v1/39376992/references?page=2